Physician profile
Walter E Donat
NPI 1144244534
$1,693.19
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,078 · 2020: $289 · 2021: $194 · 2022: $133.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $492.43 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $229.96 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $209.02 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $149.54 | 2019-2021 | |
| Actelion Pharmaceuticals US, INC. | $138.42 | 2019 | |
| Novartis Pharmaceuticals Corporation | $78.18 | 2019-2020 | |
| Mylan Specialty L.P. | $77.52 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $66.87 | 2019 | |
| Genzyme Corporation | $64.66 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $47.56 | 2019-2020 | |
| Grifols USA, LLC | $44.29 | 2019 | |
| Circassia INC. | $34.92 | 2019 | |
| Vanda Pharmaceuticals INC. | $24.45 | 2019 | |
| Amgen INC. | $17.69 | 2022 | |
| United Therapeutics Corporation | $17.68 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Walter Donat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.